Equipment-free, gold nanoparticle based semiquantitative assay of SARS-CoV-2-S1RBD IgG from fingertip blood: A practical strategy for on-site measurement of COVID-19 antibodies.
Talanta
; 246: 123498, 2022 Aug 15.
Article
in English
| MEDLINE | ID: covidwho-1805216
ABSTRACT
COVID-19 remains as a major threat to human society. A reliable, sensitive, rapid, and low requirement assay for serum neutralizing antibodies is needed as a pandemic management tool for estimation of revaccination time and implementation of "immune passport". Using gold nanoparticle (AuNR) as an immunosensor, we have established a semi-quantitative, instrument-free assay for measuring antibody level against SRAS-CoV-2 spike1 (S1) receptor binding domain (RBD) from fingertip blood samples. The testing results by the developed method correlated well with those obtained from conventional ELISA assay, indicating reliable quantitation could be achieved without use of plate reader. A declined of immunoglobulin G (IgG) antibody associated with vaccination time was observed, which agreed well with the data from other reports. The developed method provides a potentially complementary strategy for on-site measurement of COVID-19 antibodies.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Biosensing Techniques
/
Metal Nanoparticles
/
COVID-19
Type of study:
Diagnostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Talanta
Year:
2022
Document Type:
Article
Affiliation country:
J.talanta.2022.123498
Similar
MEDLINE
...
LILACS
LIS